Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;116(4):821-824.
doi: 10.14309/ajg.0000000000001134.

Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection

Jacob E Kurlander  1 , Geoffrey D Barnes, Devraj Sukul, Danielle Helminski, Alex N Kokaly, Kevin Platt, Hitinder Gurm, Sameer D Saini
Affiliations

Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection

Jacob E Kurlander et al. Am J Gastroenterol. 2021 Apr.

Abstract

Introduction: Gastrointestinal bleeding is a morbid complication of dual antiplatelet therapy (DAPT). We evaluated the extent to which contemporary trials of DAPT included steps to ensure appropriate use of proton pump inhibitor (PPI) gastroprotection and reported rates of PPI use.

Methods: A methodological review of randomized trials comparing varying durations of DAPT after percutaneous coronary intervention.

Results: Among 21 trials, none incorporated protocol procedures or guidance for prescribing PPIs. Five reported rates of PPI use (range 25.6-69.1%).

Discussion: PPI gastroprotection is overlooked in major trials of DAPT. Appropriate use of PPI gastroprotection represents an important opportunity to improve patient safety.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Geoffrey Barnes discloses grant funding from Pfizer/Bristol-Myers Squibb and consulting fees from Pfizer/Bristol-Myers Squibb, Janssen, Portola, and AMAG Pharmaceuticals. Devraj Sukul receives salary support from Blue Cross Blue Shield of Michigan (BCBSM). However, the opinions, beliefs and viewpoints expressed by the authors do not necessarily reflect those of BCBSM or any of its employees. Hitinder Gurm receives research support from Blue Cross and Blue Shield of Michigan, the National Institutes of Health Center for Accelerated Innovations, and Michigan Translational Research and Commercialization for Life Sciences Innovation Hub and is a consultant for Osprey Medical. None of the other authors report any conflicts of interest.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram
See this image and copyright information in PMC

References

    1. Berger Peter B, Bhatt Deepak L, Valentin Fuster, et al. Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. Circulation 2010;121:2575–2583. - PubMed
    1. Khan M, Siddiqui W, Alvarez C, et al. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol 2018;30:847–853. - PubMed
    1. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122:2619–2633. - PubMed
    1. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol 2016;68:1082–1115. - PubMed
    1. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSThe Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J 2018;39:213–260. - PubMed

Publication types

MeSH terms

Substances